214 related articles for article (PubMed ID: 29305275)
1. Thyroid Autoantibodies and the Clinical Presentation of Moyamoya Disease: A Prospective Study.
Lanterna LA; Galliani S; Zangari R; Conti L; Brembilla C; Gritti P; Colleoni ML; Bernucci C
J Stroke Cerebrovasc Dis; 2018 May; 27(5):1194-1199. PubMed ID: 29305275
[TBL] [Abstract][Full Text] [Related]
2. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study.
Li H; Zhang ZS; Dong ZN; Ma MJ; Yang WZ; Han C; Du MM; Liu YX; Yang H; Liu W; Duan L; Cao WC
Stroke; 2011 Apr; 42(4):1138-9. PubMed ID: 21350209
[TBL] [Abstract][Full Text] [Related]
3. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study.
Kim SJ; Heo KG; Shin HY; Bang OY; Kim GM; Chung CS; Kim KH; Jeon P; Kim JS; Hong SC; Lee KH
Stroke; 2010 Jan; 41(1):173-6. PubMed ID: 19926842
[TBL] [Abstract][Full Text] [Related]
4. Association of Hyperthyroidism and Thyroid Autoantibodies with Moyamoya Disease and Its Stroke Event: A Population-based Case-control Study and Meta-analysis.
Ahn JH; Jeon JP; Kim JE; Ha EJ; Cho WS; Park YJ; Cho NH; Choi HS; Kang HS; Son YJ; Bang JS; Oh CW
Neurol Med Chir (Tokyo); 2018 Mar; 58(3):116-123. PubMed ID: 29353860
[TBL] [Abstract][Full Text] [Related]
5. Nationwide survey on quasi-moyamoya disease in Japan.
Hayashi K; Horie N; Izumo T; Nagata I
Acta Neurochir (Wien); 2014 May; 156(5):935-40. PubMed ID: 24499994
[TBL] [Abstract][Full Text] [Related]
6. The natural clinical course of hemodynamically stable adult moyamoya disease.
Cho WS; Chung YS; Kim JE; Jeon JP; Son YJ; Bang JS; Kang HS; Sohn CH; Oh CW
J Neurosurg; 2015 Jan; 122(1):82-9. PubMed ID: 25361479
[TBL] [Abstract][Full Text] [Related]
7. Elevated thyroid autoantibodies and intracranial stenosis in stroke at an early age.
Shi Z; Zhang X; Chen Z; Liebeskind DS; Lou M
Int J Stroke; 2014 Aug; 9(6):735-40. PubMed ID: 24024979
[TBL] [Abstract][Full Text] [Related]
8. Association of moyamoya disease with thyroid autoantibodies and thyroid function: a case-control study and meta-analysis.
Lei C; Wu B; Ma Z; Zhang S; Liu M
Eur J Neurol; 2014 Jul; 21(7):996-1001. PubMed ID: 24684272
[TBL] [Abstract][Full Text] [Related]
9. Transient Ischemic Attack in Pediatric Patients With Moyamoya Disease: Clinical Features, Natural History, and Predictors of Stroke.
Zhao M; Zhang D; Wang S; Zhang Y; Wang R; Zhao J
Pediatr Neurol; 2017 Oct; 75():48-54. PubMed ID: 28778481
[TBL] [Abstract][Full Text] [Related]
10. Down syndrome and moyamoya: clinical presentation and surgical management.
See AP; Ropper AE; Underberg DL; Robertson RL; Scott RM; Smith ER
J Neurosurg Pediatr; 2015 Jul; 16(1):58-63. PubMed ID: 25837890
[TBL] [Abstract][Full Text] [Related]
11. Distinct Clinical and Radiographic Phenotypes in Pediatric Patients With Moyamoya.
Kaseka ML; Slim M; Muthusami P; Dirks PB; Westmacott R; Kassner A; Bhathal I; Williams S; Shroff M; Logan W; Moharir M; MacGregor DL; Pulcine E; deVeber GA; Dlamini N
Pediatr Neurol; 2021 Jul; 120():18-26. PubMed ID: 33962345
[TBL] [Abstract][Full Text] [Related]
12. Disparities in the symptomatic presentation of Moyamoya disease in the United States: A nationwide all-payer analysis.
Fuentes AM; Chiu RG; Mehta AI
J Clin Neurosci; 2021 May; 87():92-96. PubMed ID: 33863543
[TBL] [Abstract][Full Text] [Related]
13. Thyroid antibodies are associated with stenotic lesions in the terminal portion of the internal carotid artery.
Tanaka M; Sakaguchi M; Yagita Y; Gon Y; Yoshikawa K; Takahashi T; Fukunaga R; Mochizuki H; Kitagawa K
Eur J Neurol; 2014 Jun; 21(6):867-73. PubMed ID: 24602238
[TBL] [Abstract][Full Text] [Related]
14. Immune response profiling identifies autoantibodies specific to Moyamoya patients.
Sigdel TK; Shoemaker LD; Chen R; Li L; Butte AJ; Sarwal MM; Steinberg GK
Orphanet J Rare Dis; 2013 Mar; 8():45. PubMed ID: 23518061
[TBL] [Abstract][Full Text] [Related]
15. Clinical course of asymptomatic adult moyamoya disease.
Jo KI; Yeon JY; Hong SC; Kim JS
Cerebrovasc Dis; 2014; 37(2):94-101. PubMed ID: 24435045
[TBL] [Abstract][Full Text] [Related]
16. Anti-alpha-fodrin autoantibodies in Moyamoya disease.
Ogawa K; Nagahiro S; Arakaki R; Ishimaru N; Kobayashi M; Hayashi Y
Stroke; 2003 Dec; 34(12):e244-6. PubMed ID: 14657555
[TBL] [Abstract][Full Text] [Related]
17. Impact of thyroid autoantibodies on functional outcome in patients with acute ischemic stroke.
Cho HJ; Kim SS; Sung SM; Jung DS
J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1915-20. PubMed ID: 24796663
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with the presentation of moyamoya in childhood.
Amlie-Lefond C; Ellenbogen RG
J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1204-10. PubMed ID: 25866319
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and disease progression in moyamoya disease patients with Graves disease.
Chen JB; Lei D; He M; Sun H; Liu Y; Zhang H; You C; Zhou LX
J Neurosurg; 2015 Oct; 123(4):848-55. PubMed ID: 25859801
[TBL] [Abstract][Full Text] [Related]
20. Universal Bypass for Treatment of Symptomatic Moyamoya Disease or Moyamoya Syndrome. Analysis of a Personal Case Series on Behalf of the Italian Moyamoya Association.
Lanterna LA; Brembilla C; Gritti P; Bernucci C
Acta Neurochir Suppl; 2016; 123():129-32. PubMed ID: 27637639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
